European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with obesity-related HFpEF.
Weight Loss, Ozempic
At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...
There is soaring demand for weight-loss drugs in the GLP-1 class, and the company will now sell it to certain professions for ...
One of the world’s largest drug manufacturers is suing a small east metro wellness center over the way it marketed and sold a ...
In the heavyweight title match between weight loss meds, we have ourselves a victor.In the battle between Novo Nordisk’s ...
Researchers found that patients with obesity had an average weight loss of 12.9% with semaglutide vs 5.6% with liraglutide ...
Compounding pharmacies that offer their own homebrew GLP-1 drugs are the new designer smoke shops: Illegal, unsafe, and ...
Medicare may cover Wegovy for adults with cardiovascular disease and either obesity or overweight. Learn more about Medicare ...
Nestlé is launching new frozen meals designed for busy Americans who just aren't that hungry anymore — or who may be ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback